Mirae Asset Global ETFs Holdings
CPRX

Mirae Asset Global ETFs Holdings’s Catalyst Pharmaceutical CPRX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Buy
62,782
+14
+0% +$334 ﹤0.01% 1302
2025
Q4 		$1.46M Buy
62,768
+951
+2% +$21.2K ﹤0.01% 1316
2025
Q3 		$1.22M Sell
61,817
-6,371
-9% -$131K ﹤0.01% 1373
2025
Q2 		$1.48M Sell
68,188
-3,864
-5% -$91.2K ﹤0.01% 1249
2025
Q1 		$1.75M Buy
72,052
+3,800
+6% +$85.6K ﹤0.01% 1217
2024
Q4 		$1.43M Buy
68,252
+2,252
+3% +$48.4K ﹤0.01% 1351
2024
Q3 		$1.31M Buy
66,000
+2,071
+3% +$38.4K ﹤0.01% 1386
2024
Q2 		$987K Buy
+63,929
New +$995K ﹤0.01% 1459

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Mirae Asset Global ETFs Holdings's CPRX Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Catalyst Pharmaceutical (CPRX) stake by 0.02% in Q1 2026, buying an estimated $334 and bringing the position to 62,782 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1302.

Mirae Asset Global ETFs Holdings first reported a position in CPRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.75M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 62,782 shares of Catalyst Pharmaceutical worth $1.55M as of Q1 2026.
  • Mirae Asset Global ETFs Holdings bought 14 Catalyst Pharmaceutical shares in Q1 2026, an estimated $334.
  • Catalyst Pharmaceutical made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #1302 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 8 quarters since.
  • Mirae Asset Global ETFs Holdings's Catalyst Pharmaceutical position peaked at $1.75M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.